![\"Zacks](\"https:\/\/www.europesays.com\/germany\/wp-content\/uploads\/2026\/06\/223c2b6b895da71a3f5a68dd668c3ad1.jpeg\")
Zacks Investment Research <\/p>\nBASF SE\u2019s BASFY Bemotrizinol, marketed as Tinosorb S, has been approved by the U.S. Food and Drug Administration (FDA) as a sunscreen active ingredient. This approval serves as a landmark, paving the way for the introduction of the first new UV filter to American consumers in 27 years, a major advancement in sun protection technology.<\/p>\n
Originally developed by Ciba Specialty Chemicals and later acquired by BASFY, Bemotrizinol, known chemically as Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, has been widely used around the world for years as it provides highly effective broad-range protection against both UVA and UVB radiation.<\/p>\n
Tinosorb S is recognized for its exceptional efficacy and photostability, maintaining its effectiveness even during prolonged sun exposure. With absorption peaks at approximately 310 nm and 340 nm, it offers comprehensive protection against wavelengths responsible for skin damage and premature aging.<\/p>\n
Tinosorb S also comes added with formulations for more photo-unstable UV filters, helping improve the performance of less stable sunscreen ingredients such as avobenzone. This capability is especially valuable in the U.S. market, where options for strong UVA protection have been limited. Together with avobenzone or Z-COTE zinc oxides, Tinosorb S is able to achieve a wavelength above 370 nm, providing broad-spectrum protection.<\/p>\n
Its large molecular structure is another key advantage, which results in low percutaneous absorptionand a reduced risk of irritation. These characteristics make it an excellent choice for advanced sunscreen formulations designed for sensitive skin.<\/p>\n
The FDA approval of Tinosorb S expands BASF\u2019s sun care portfolio and provides formulators with new opportunities to create more effective, broad-spectrum sunscreen products for American consumers, incorporating years of photoprotection.<\/p>\n
BASFY has gained 18.5% over the past year compared with the industry\u2019s 7.4% growth.<\/p>\n
Zacks Investment Research <\/p>\n
Image Source: Zacks Investment Research<\/p>\n
BASFY\u2019s\u00a0Zacks Rank & Key Picks <\/p>\n
BASFY currently carries a Zacks Rank #3 (Hold).<\/p>\n
Some better-ranked stocks in the Basic Materials space are\u00a0Albemarle Corporation ALB, CF Industries Holdings, Inc. CF andAvino Silver & Gold Mines Ltd. ASM.<\/p>\n
While ALB sports a Zacks Rank #1 (Strong Buy) at present, CF and ASM carry a Zacks Rank #2 (Buy) each. You can see\u00a0the complete list of today\u2019s Zacks #1 Rank stocks here.<\/p>\n
The Zacks Consensus Estimate for ALB\u2019s 2026 earnings is pinned at $12.39 per share, indicating a 1,668.35% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB\u2019s shares have jumped 179.5% over the past year.<\/p>\n","protected":false},"excerpt":{"rendered":"BASF SE\u2019s BASFY Bemotrizinol, marketed as Tinosorb S, has been approved by the U.S. Food and Drug Administration…\n","protected":false},"author":2,"featured_media":19760,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21106],"tags":[20305,22849,33277,33276,21135],"class_list":["post-36939","post","type-post","status-publish","format-standard","has-post-thumbnail","category-basf","tag-basf","tag-consensus-estimate","tag-sunscreen-ingredients","tag-tinosorb-s","tag-zacks-investment-research"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/36939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/comments?post=36939"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/36939\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media\/19760"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media?parent=36939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/categories?post=36939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/tags?post=36939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}